Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Wu

Showing results (41-50 of 115) with videos related to

Pageof 12
Sort By:
Current Medical Research and Opinion|February 5, 2015
Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysisStephanie Chen, Elyse Swallow, Nanxin Li, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 8, 2023
Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's DiseaseYan Song, Jian-Yu E, Tracy Guo, et al.
Journal of Medical Economics|September 6, 2013
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medicationsJuliana Setyawan, Annie Guérin, Paul Hodgkins, et al.
Journal of Medical Economics|August 14, 2013
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adultsJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Plos One|December 5, 2019
Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting systemRaymond K Cross, Michael Chiorean, Francis Vekeman, et al.
Scientific Reports|February 2, 2019
Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966Maria Lapteva, Sergio Del Río-Sancho, Eric Wu, et al.
Inflammatory Bowel Diseases|September 18, 2010
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Si-Tien Wang, et al.
Inflammatory Bowel Diseases|July 24, 2014
The impact of moderate-to-severe Crohn's Disease on employees' salary growthEdward V Loftus, Martha Skup, Ahmet Burak Ozbay, et al.
Current Medical Research and Opinion|March 17, 2015
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical dataVijayveer Bonthapally, Eric Wu, Alexander Macalalad, et al.
Physiological Reviews|April 27, 2023
Leveraging physiology and artificial intelligence to deliver advancements in health careAngela Zhang, Zhenqin Wu, Eric Wu, et al.
Pageof 12

Showing results (41-50 of 115) with videos related to

Sort By:
Pageof 12
Current Medical Research and Opinion|February 5, 2015
Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysisStephanie Chen, Elyse Swallow, Nanxin Li, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 8, 2023
Treatment Patterns and Healthcare Resource Use in Medicare Beneficiaries with Parkinson's DiseaseYan Song, Jian-Yu E, Tracy Guo, et al.
Journal of Medical Economics|September 6, 2013
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medicationsJuliana Setyawan, Annie Guérin, Paul Hodgkins, et al.
Journal of Medical Economics|August 14, 2013
Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adultsJuliana Setyawan, Paul Hodgkins, Annie Guérin, et al.
Plos One|December 5, 2019
Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting systemRaymond K Cross, Michael Chiorean, Francis Vekeman, et al.
Scientific Reports|February 2, 2019
Fractional laser ablation for the targeted cutaneous delivery of an anti-CD29 monoclonal antibody - OS2966Maria Lapteva, Sergio Del Río-Sancho, Eric Wu, et al.
Inflammatory Bowel Diseases|September 18, 2010
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's diseaseEdward V Loftus, Scott J Johnson, Si-Tien Wang, et al.
Inflammatory Bowel Diseases|July 24, 2014
The impact of moderate-to-severe Crohn's Disease on employees' salary growthEdward V Loftus, Martha Skup, Ahmet Burak Ozbay, et al.
Current Medical Research and Opinion|March 17, 2015
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical dataVijayveer Bonthapally, Eric Wu, Alexander Macalalad, et al.
Physiological Reviews|April 27, 2023
Leveraging physiology and artificial intelligence to deliver advancements in health careAngela Zhang, Zhenqin Wu, Eric Wu, et al.
Pageof 12